Quipt Home Medical Corp SEC Filings

Quipt Home Medical Corp. filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership, related-party dealings, and auditor fees. The company had 44,329,972 common shares outstanding as of January 23, 2026.

The filing describes a pending Arrangement under which Purchaser entities agreed to acquire all Quipt shares for US$3.65 per share, with key shareholders and directors committed to vote in favor. It outlines a four-member board, fully independent key committees, and a new 2024 Equity Incentive Plan covering up to 8,420,494 shares, with 2,903,753 shares granted in fiscal 2025.

For 2025, CEO Gregory Crawford received total compensation of $3,043,176, largely in share-based awards, while CFO Hardik Mehta received $1,473,957. The report details change-in-control retention and severance terms for senior executives, related-party facility leases totaling future payments of $3,807,159 as of 2025, and auditor fees of $890,183 for 2025.

Quipt Home Medical Corp. reports that the U.S. Hart-Scott-Rodino antitrust waiting period has expired for its planned acquisition, under which a purchaser will acquire all outstanding Quipt common shares for $3.65 per share in cash by way of a court-approved plan of arrangement in British Columbia. The expiration of the HSR waiting period removes a key U.S. antitrust condition but the transaction still depends on other customary closing conditions, including approval by Quipt shareholders. The company reminds investors that completion of the deal is uncertain and subject to risks, and directs securityholders to review the forthcoming definitive management information circular and proxy statement before voting.

Quipt Home Medical Corp. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer reporting a passive ownership stake. The reporting persons disclose beneficial ownership of 2,476,409 common shares of Quipt Home Medical, representing 5.62% of the class. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all 2,476,409 shares.

The shares are held by certain funds and managed accounts for which Glazer Capital acts as investment manager, with Paul J. Glazer as Managing Member of Glazer Capital. The filers state that the securities were not acquired and are not held for the purpose of changing or influencing control of Quipt Home Medical, indicating a passive investment intent under Schedule 13G.

Quipt Home Medical Corp. filed a report stating that on December 30, 2025 it issued a notice of meeting for a special meeting of shareholders scheduled for March 3, 2026. The notice, attached as Exhibit 99.1, relates to a proposed transaction involving Quipt, 1567208 B.C. LTD, and REM Aggregator, LLC.

The company highlights that expectations about the timing and completion of this proposed transaction are forward-looking statements and may change if regulatory, court, shareholder, or other approvals, or closing conditions, are delayed or not obtained. Quipt indicates it will file a detailed proxy statement and management information circular on Schedule 14A, which shareholders are urged to review in full when available before deciding how to vote on the proposed transaction.

Quipt Home Medical Corp.'s President and CEO Gregory John Crawford, who also serves as a director, reported exercising stock options for 581,000 common shares on 12/05/2025 at an exercise price of $1.11 per share, based on converting a C$1.50 exercise price at a 0.74 exchange rate.

After these transactions he directly owns 3,351,196 common shares. Additional holdings include 22,500 common shares held by his spouse and 1,216,832 common shares held by a family trust for his children, for which he disclaims beneficial ownership. Options corresponding to 581,000 of his shares and 2,500 of his spouse’s shares, expiring on 04/09/2028, were fully exercised in these moves, leaving no remaining options from these specific grants.

Quipt Home Medical Corp. disclosed that it has released its financial results for the year ended September 30, 2025, in a press release dated December 15, 2025. This update relates to the company’s results of operations and financial condition and is being reported under a current report to regulators.

The press release is furnished as Exhibit 99.1 and includes financial information prepared under U.S. GAAP as well as Non-GAAP financial measures. It also provides reconciliations between these Non-GAAP measures and the most directly comparable GAAP figures, along with management’s explanation of why these alternative metrics are useful to investors. The information in this report and the exhibit is expressly treated as furnished, not filed, under U.S. securities laws.

Quipt Home Medical Corp., a U.S. durable/home medical equipment provider focused on respiratory care across 27 states, files its annual report for the year ended September 30, 2025. The company has agreed to be acquired by entities affiliated with Kingswood Capital Management for $3.65 per share in cash, after which it is expected to go private and its shares will be delisted from Nasdaq and the TSX, subject to shareholder, court and regulatory approvals in the first half of 2026.

Quipt highlights an acquisitive growth strategy, including the purchase of Mediserve Medical Equipment of Kingsport for about $2.6 million and a 60% stake in Hart Medical Equipment with additional debt repayment funded under its senior credit facility. The report emphasizes reliance on Medicare and Medicaid reimbursement, competitive pressure from national and regional DME/HME providers, and detailed risk disclosures covering supply chain and labor constraints, inflation and interest rates, cybersecurity, complex U.S. healthcare regulations, and potential changes to government and private payor payment policies.

Quipt Home Medical Corp. has entered into a definitive Arrangement Agreement to be acquired by entities affiliated with Kingswood Capital Management for US$3.65 in cash per common share via a court-approved plan of arrangement under British Columbia corporate law. The board unanimously approved the deal, judged the cash consideration fair from a financial point of view, and plans to recommend that shareholders vote in favor at a special meeting.

At closing, each common share (other than validly dissenting shares) will be exchanged for US$3.65 in cash, options will vest and be cashed out to the extent their exercise price is below that amount, and restricted share units will be settled for cash at US$3.65, all less applicable taxes. Following completion, Quipt’s shares are expected to be de-listed from the Nasdaq Capital Market and the Toronto Stock Exchange and de-registered in the United States, and the company will cease to be a Canadian reporting issuer.

The parties expect to close in the first half of 2026, subject to conditions including required shareholder approvals (such as a 66⅔% vote threshold), court approval, antitrust clearance under the Hart-Scott-Rodino Act, no Material Adverse Effect, and limits on dissent rights. Shareholders and certain insiders holding approximately 20.9% of the outstanding shares have signed voting support agreements in favor of the transaction, and Kingswood has provided an equity commitment to fund the cash consideration and related costs.

Quipt Home Medical Corp. reported that on August 27, 2025 it issued a press release confirming receipt of another unsolicited, non-binding and indicative proposal from Forager Capital Management, LLC. This indicates external interest in the company but does not represent a firm offer or agreement. The press release detailing the proposal is included as Exhibit 99.1 and incorporated by reference. The company is furnishing this information under Regulation FD, meaning it is sharing the same update with all investors at the same time.